The BIOSS Lim C pharmacoactive Stent has characteristics of design that makes it very suitable for the treatment of bifurcational lesions . The objective of the study is providing deeper knowledge into the results of this stent in the treatment of bifurcational lesions.
The BIOSS Lim C pharmacoactive Stent has characteristics of design that makes it very suitable for the treatment of bifurcational lesions . The objective of the study is providing deeper knowledge into the results of this stent in the treatment of bifurcational lesions.
Study Type
OBSERVATIONAL
Enrollment
100
Coronary angioplasty with BiOSS LIM C stent implantation
Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain
RECRUITINGHospital Universitari Vall d'Hebron
Barcelona, Spain
RECRUITINGHospital Universitario de León
León, Spain
RECRUITINGSuccessful angioplasty
After angiography: TIMI (thrombolysis in myocardial infarction ) 3 (both branches). With respect to reference diameter, none of the segments treated with stent has a residual stenosis\> 30% or\> 50% in those not treated with stent.
Time frame: 1 day
MACE
Cumulative rate of major adverse cardiovascular events (MACE) including cardiac death, myocardial infarction (MI) and repeated revascularization of the target lesion (TLR)
Time frame: 30 days
MACE
Cumulative rate of major adverse cardiovascular events (MACE) including cardiac
Time frame: 1 year
Target vessel revascularization
Target vessel revascularization
Time frame: 30 days
Percentage of stent struts malposition
Percentage of stent struts malposition
Time frame: 30 days
contrast media volume
contrast media volume
Time frame: 1 day
Angioplasty time
Angioplasty time
Time frame: 1 day
Imanol Otaegui
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.